December 2018—Precipio launched a new ICEme kit using the company’s proprietary Ice-Cold PCR technology.
The kit provides physicians with the ability to use a liquid biopsy to identify patients eligible for tyrosine kinase inhibitor therapies through analysis of tumor DNA for these EGFR mutations.
The kit complements Precipio’s previously launched TKI-resistance detection kit, which includes assays for EGFR exon 20 T790M and C797S resistance mutations. The new kit enriches and detects cancer mutations within EGFR exons 18, 19, 20, and 21 and is available on qPCR and Sanger diagnostic platforms, with a level of sensitivity as low as 0.1 percent.
Precipio, 203-787-7888